ArticleDiscover oncology2026
The pyroptosis and inflammatory response-related long noncoding RNA signature as a novel prognostic biomarker of head and neck squamous cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) represents a significant malignancy arising from mucosal epithelia. Pyroptosis, a gasdermin-mediated programmed necrotic cell death mechanism, has emerged as a critical process in tumor biology due to its association with inflammatory factor release and immune microenvironment modulation. While the interplay between inflammatory responses and tumorigenesis is well-established, the regulatory role of pyroptosis-related long non-coding RNAs (lncRNAs) in HNSCC progression remains poorly characterized. This investigation aims to elucidate the prognostic significance of pyroptosis-associated lncRNAs in HNSCC and their potential impact on tumor immunobiology.
methodsPrognostic lncRNA signatures were subsequently established through univariate Cox regression followed by LASSO (Least Absolute Shrinkage and Selection Operator) and multivariate Cox proportional hazards modeling. The predictive capacity of the derived signature was validated through survival analysis, nomogram construction, and receiver operating characteristic (ROC) curve assessment. Immune microenvironment characteristics were investigated via Gene Set Enrichment Analysis (GSEA) and immune checkpoint expression profiling.
resultsOur analysis identified 18 differentially expressed pyroptosis-related lncRNAs with prognostic significance in HNSCC. Kaplan-Meier survival curves demonstrated superior overall survival in low-risk patients stratified by the lncRNA signature. The prognostic model achieved an area under the curve (AUC) of 0.663, outperforming conventional clinicopathological parameters. GSEA revealed significant enrichment of immune-related pathways in the low-risk cohort, including T-cell activation and cytokine-mediated signaling. Comprehensive immune profiling demonstrated differential activity in 34 immune checkpoints between risk groups, including CTLA4, PDCD1, and LAG3. Significant intergroup differences were observed in immunological parameters including HLA expression, T-cell cytolytic activity, and TNF-mediated signaling.
conclusionThis study establishes a novel 18-lncRNA signature associated with pyroptosis and inflammatory responses in HNSCC, demonstrating robust prognostic capability and significant correlation with tumor immune landscape alterations. The identified biomarkers provide insights into pyroptosis-mediated immunomodulation and present potential targets for therapeutic intervention. Our findings underscore the clinical utility of pyroptosis-related lncRNA profiling in HNSCC risk stratification and immunotherapy response prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.